Nooka AK - Search Results

1

Teclistamab in Relapsed or Refractory Multiple Myeloma.

Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, Nooka AK, Martin T, Rosinol L, Chari A, Karlin L, Benboubker L, Mateos MV, Bahlis N, Popat R, Besemer B, Martínez-López J, Sidana S, Delforge M, Pei L, Trancucci D, Verona R, Girgis S, Lin SXW, Olyslager Y, Jaffe M, Uhlar C, Stephenson T, Van Rampelbergh R, Banerjee A, Goldberg JD, Kobos R, Krishnan A, Usmani SZ. Moreau P, et al. Among authors: nooka ak. N Engl J Med. 2022 Aug 11;387(6):495-505. doi: 10.1056/NEJMoa2203478. Epub 2022 Jun 5. N Engl J Med. 2022. PMID: 35661166 Free PMC article. Clinical Trial.

2

Supportive therapies in multiple myeloma.

Gleason C, Nooka A, Lonial S. Gleason C, et al. J Natl Compr Canc Netw. 2009 Oct;7(9):971-9. doi: 10.6004/jnccn.2009.0064. J Natl Compr Canc Netw. 2009. PMID: 19878640 Review.

3

The importance of complete response in outcomes in myeloma.

Nooka A, Kaufman J, Lonial S. Nooka A, et al. Cancer J. 2009 Nov-Dec;15(6):465-72. doi: 10.1097/PPO.0b013e3181c51cd4. Cancer J. 2009. PMID: 20010165 Review.

4

Sequential or combination therapy for multiple myeloma.

Nooka A, Lonial S. Nooka A, et al. Expert Rev Hematol. 2012 Oct;5(5):533-45. doi: 10.1586/ehm.12.49. Expert Rev Hematol. 2012. PMID: 23146057 Review.

5

Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib.

Nooka A, Gleason C, Casbourne D, Lonial S. Nooka A, et al. Biologics. 2013;7:13-32. doi: 10.2147/BTT.S24580. Epub 2013 Jan 30. Biologics. 2013. PMID: 23386784 Free PMC article.

6

Bortezomib-containing induction regimens in transplant-eligible myeloma patients: a meta-analysis of phase 3 randomized clinical trials.

Nooka AK, Kaufman JL, Behera M, Langston A, Waller EK, Flowers CR, Gleason C, Boise LH, Lonial S. Nooka AK, et al. Cancer. 2013 Dec 1;119(23):4119-28. doi: 10.1002/cncr.28325. Epub 2013 Sep 4. Cancer. 2013. PMID: 24005889 Free article. Clinical Trial.

7

Vinorelbine, paclitaxel, etoposide, cisplatin, and cytarabine (VTEPA) is an effective second salvage therapy for relapsed/refractory Hodgkin lymphoma.

Sinha R, Shenoy PJ, King N, Lechowicz MJ, Bumpers K, Hutcherson D, Arellano M, Langston A, Kaufman J, Heffner LT Jr, Waller EK, Nooka A, Flowers CR, Lonial S. Sinha R, et al. Clin Lymphoma Myeloma Leuk. 2013 Dec;13(6):657-63. doi: 10.1016/j.clml.2013.05.007. Epub 2013 Oct 2. Clin Lymphoma Myeloma Leuk. 2013. PMID: 24094894

8

Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients.

Nooka AK, Kaufman JL, Muppidi S, Langston A, Heffner LT, Gleason C, Casbourne D, Saxe D, Boise LH, Lonial S. Nooka AK, et al. Leukemia. 2014 Mar;28(3):690-3. doi: 10.1038/leu.2013.335. Epub 2013 Nov 13. Leukemia. 2014. PMID: 24220275

9

Predictors of survival outcomes in phase 1 relapsed or refractory multiple myeloma patients.

Barbee MS, Nooka A, Kaufman JL, Kim S, Chen Z, Heffner LT Jr, Lonial S, Harvey RD. Barbee MS, et al. Cancer. 2015 Mar 15;121(6):853-62. doi: 10.1002/cncr.29136. Epub 2014 Nov 6. Cancer. 2015. PMID: 25377852 Free article. Clinical Trial.

10

Treatment options for relapsed and refractory multiple myeloma.

Nooka AK, Kastritis E, Dimopoulos MA, Lonial S. Nooka AK, et al. Blood. 2015 May 14;125(20):3085-99. doi: 10.1182/blood-2014-11-568923. Epub 2015 Apr 2. Blood. 2015. PMID: 25838342 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

180 results

Search Page